Compare ELVN & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | DAVE |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.5B |
| IPO Year | 2020 | N/A |
| Metric | ELVN | DAVE |
|---|---|---|
| Price | $38.84 | $174.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $43.40 | ★ $309.63 |
| AVG Volume (30 Days) | ★ 1.3M | 582.3K |
| Earning Date | 05-13-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.28 |
| Revenue Next Year | N/A | $17.38 |
| P/E Ratio | ★ N/A | $17.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $65.46 |
| 52 Week High | $40.62 | $286.45 |
| Indicator | ELVN | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 72.06 | 38.38 |
| Support Level | $18.04 | $156.92 |
| Resistance Level | N/A | $222.03 |
| Average True Range (ATR) | 2.47 | 11.62 |
| MACD | 0.95 | -5.02 |
| Stochastic Oscillator | 92.39 | 21.41 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.